Altogether however, the previously presented prospects of selectively blocking GRP78 in future clinical applications, with the intent to achieve chemoprevention, chemosensitization, or other cancer therapeutic outcomes, are complicated by two important aspects. The gene discussed is HSPA5; the disease is cancer.